Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Wave Life Sciences's Enterprise Value is $546.11 Mil.
Wave Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-191.58 Mil. Therefore, Wave Life Sciences's EV-to-OCF for today is -2.85.
The historical rank and industry rank for Wave Life Sciences's EV-to-OCF or its related term are showing as below:
WVE'
s EV-to-OCF Range Over the Past 10 Years
Min: -183.3 Med: -5.2 Max: 0.1
Current: -2.85
During the past 13 years, the highest EV-to-OCF of Wave Life Sciences was 0.10. The lowest was -183.30. And the median was -5.20.
WVE's EV-to-OCF is ranked worse than 53.69% of 1408
companies
in the Biotechnology industry
Industry Median: -3.715
vs WVE: -2.85
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wave Life Sciences (NAS:WVE) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wave Life Sciences's PE Ratio (TTM) for today is calculated as:
Wave Life Sciences's share price for today is $5.04.
Wave Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Wave Life Sciences EV-to-OCF Related Terms
Wave Life Sciences EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Wave Life Sciences's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Wave Life Sciences's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wave Life Sciences EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wave Life Sciences's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Wave Life Sciences's EV-to-OCF falls into.
Wave Life Sciences's current Enterprise Value is $546.11 Mil.
Wave Life Sciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-191.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wave Life Sciences (WVE) has a EV-to-OCF of -2.85 as of Aug. 29, 2026. According to the industry distribution chart, Wave Life Sciences ranks #756 out of 1408 companies in the Biotechnology industry, placing it in the top 53.7%.
Is Wave Life Sciences' EV-to-OCF too high?
Wave Life Sciences' current EV-to-OCF is -2.85. Based on the distribution chart, Wave Life Sciences ranks #756 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Wave Life Sciences has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wave Life Sciences' EV-to-OCF compare to FBRX and SVRA?
According to the Biotechnology industry distribution chart, Wave Life Sciences ranks #756 out of 1408 companies for EV-to-OCF. This places Wave Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Wave Life Sciences's current EV-to-OCF is -2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wave Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Wave Life Sciences (WVE) is currently considered Modestly Overvalued. The stock's GF Value™ is $3.93, compared to a current price of $5.04 — trading 28.2% above its estimated fair value. The current EV-to-OCF is -2.85. Wave Life Sciences' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Wave Life Sciences (WVE), the current EV-to-OCF is -2.85 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wave Life Sciences (WVE) Overvalued in 2026?
Based on GuruFocus' analysis, Wave Life Sciences stock appears to be overvalued.
The current stock price of $5.04 is trading 28.2% above its estimated GF Value™ of $3.93.
GuruFocus considers Wave Life Sciences to be Modestly Overvalued.
Key valuation signals for WVE:
EV-to-OCF: -2.85
GF Value™: $3.93 vs. price of $5.04 (28.2% above fair value)
No single metric tells the full story. See the WVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
60GF Score
Get the complete analysis for WVE
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WVE has been successfully added to your 
